Specialists & Providers
Diagnostic Biomarkers
Treatments & Interventions
Leuprolide acetate
substance
Doxazosin mesylate
substance
Tamsulosin hydrochloride
substance
Doxazosin
substance
Tamsulosin
substance
Dutasteride
substance
Finasteride
substance
Terazosin
substance
Prazosin hydrochloride
substance
Prazosin
substance
Alfuzosin hydrochloride
substance
Alfuzosin
substance
Leuprorelin
substance
Saw palmetto extract
substance
Terazosin hydrochloride
substance
Silodosin
substance
Terazosin hydrochloride anhydrous
substance
Research Evidence
Peer-reviewed studies linked via MeSH term "Prostatic Hyperplasia" from the MEDLINE/PubMed database.
Research data from MEDLINE/PubMed
Signs & Symptoms
Based on Human Phenotype Ontology (HPO) disease-phenotype annotations.
Quick Facts
- SNOMED CT
- 266569009
- UMLS CUI
- C2937421
- Fully Specified Name
- Benign prostatic hyperplasia (disorder)
- Specialists
- 2
- Diagnostic Biomarkers
- 1
- HPO Phenotypes
- 1
- Known Treatments
- 17
Related Health Goals
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.